BPC-157 10mg · Research brief

What Is BPC 157? Sequence, Mechanism and Research

Real Peptides Research TeamEditorial

Updated February 25, 20269 min read

48 WORDS

Short answer

Nearly the entire published record on BPC 157 comes from rats and mice. That isn't a knock against the compound. It's an accurate description of where the data lives, and search results routinely compress three decades of rodent injury models into phrasing that reads like settled human medicine.

Key takeaways

BPC 157 is a synthetic 15-amino-acid peptide with the sequence GEPPPGKPADDAGLV, molecular formula C62H98N16O22, and CAS number 137525-51-0.
The sequence derives from a fragment of a protein described in human gastric juice, but research material is built by solid-phase peptide synthesis, never extracted from tissue.
No high-affinity receptor for the peptide has been characterised in the published literature, so all reported mechanisms are described as downstream signalling, chiefly through VEGFR2, Akt, eNOS and the nitric oxide system.
Reported anti-inflammatory findings, including reduced TNF-alpha and IL-6 expression, come from rodent colitis and NSAID-lesion models, and no controlled human arthritis trials appear in the literature.
The FDA placed the compound in Category 2 of its bulk drug substances review in 2023, and it is not approved as a drug product in any indication.
Identity verification matters more than a headline purity number: match CAS, molecular weight and salt form on the batch certificate before a vial enters a study.

We supply research-grade peptides to laboratories, and BPC 157 is among the most requested compounds our team ships. Researchers new to it ask the same thing every week: separate what is documented from what is extrapolation.

What is BPC 157?

BPC 157 is a synthetic pentadecapeptide, a chain of 15 amino acids with the sequence GEPPPGKPADDAGLV, corresponding to a partial sequence of a protein identified in human gastric juice. It carries CAS number 137525-51-0, is supplied strictly for laboratory research, and has been studied almost entirely in animal models of tissue injury.

The oversimplification worth correcting up front: BPC 157 is not a single-target molecule with a clean lock-and-key story. No high-affinity receptor for it has been characterised in the published literature, so every credible mechanistic paper describes downstream signalling instead. What follows covers what the peptide is made of, how it is produced, the pathways studies report, and exactly where the evidence stops.

What the peptide is made of, and how it is produced

BPC 157 is made of 15 amino acids in a fixed order: glycine, glutamic acid, proline, proline, proline, glycine, lysine, proline, alanine, aspartic acid, aspartic acid, alanine, glycine, leucine, valine. In single-letter code that reads GEPPPGKPADDAGLV. The molecular formula is C62H98N16O22 and the molecular weight sits at roughly 1419.5 g/mol for the free base. The sequence corresponds to a fragment of Body Protection Compound, a protein described in human gastric juice by the research group at the University of Zagreb School of Medicine that first characterised the peptide in the 1990s.

Nothing in a modern research vial is extracted from tissue. BPC 157 is produced by solid-phase peptide synthesis, where the chain is assembled one residue at a time on a resin support using Fmoc protecting-group chemistry, then cleaved, purified by reverse-phase HPLC, and verified by mass spectrometry. It ships as a white lyophilised powder, usually as an acetate salt. An arginate salt form also circulates, and the two are not interchangeable on paper, so the salt form belongs on the certificate of analysis rather than buried in a product blurb.

Storage is unglamorous and matters more than most buyers expect. Lyophilised BPC 157 is kept frozen, desiccated and shielded from light, and repeated freeze-thaw cycling is the most common avoidable cause of degradation in a working lab. Our team's consistent observation across supplier documentation is that identity, not the headline purity percentage, is where sourcing quietly fails.

How the compound behaves in animal models

Ask how BPC 157 actually works and the honest answer is that the literature describes pathways, not a receptor. No characterised high-affinity BPC 157 receptor appears in the published record, which is the single most important caveat sitting underneath every mechanism claim you will read.

The most consistently reported pathway is angiogenic. Studies report upregulation of VEGFR2 (vascular endothelial growth factor receptor 2) with downstream activation of Akt and eNOS (endothelial nitric oxide synthase), the enzyme that generates nitric oxide inside blood-vessel lining cells and drives new capillary formation in injury models. Related work describes interaction with the nitric oxide system in both directions: rodent studies report that the peptide counteracts the effects of L-NAME, a nitric oxide synthase blocker, while also modulating responses to L-arginine. Authors tend to frame that bidirectional pattern as homeostatic rather than simply stimulatory.

In cell culture, research on tendon fibroblasts reports increased outgrowth and migration linked to the FAK-paxillin pathway, focal adhesion kinase and its partner protein being the machinery that governs how a cell grips a surface and crawls across it. The same body of work reports upregulated growth hormone receptor expression in those fibroblasts.

So how does BPC 157 help with inflammation in these models? Studies report reduced expression of pro-inflammatory cytokines, TNF-alpha and IL-6 among them, in rodent colitis and NSAID-induced gastrointestinal lesion models. On arthritis specifically, the published literature does not contain controlled human arthritis trials, and joint-related findings come from animal injury models rather than from patients.

What researchers study it for, and its regulatory status

Published preclinical work on BPC 157 clusters into a handful of model families: gastrointestinal mucosal injury including NSAID-induced lesions and experimental colitis, transected or crushed tendon, ligament and muscle in rodents, peripheral nerve injury, skin wound closure, and vascular occlusion models where researchers track redirected collateral blood flow. Those are research questions, not indications.

Then there is the forum problem. Threads about BPC 157 are overwhelmingly self-reported, unblinded and unverifiable, and no volume of anecdote converts a preclinical compound into a characterised human therapeutic. Human pharmacokinetics for BPC 157 are not established in the published literature. Half-life, bioavailability and clearance in people simply are not specified, so any source quoting a confident human half-life figure should be asked for the citation.

Regulatory footing is clearer than the science. BPC 157 is not approved by the FDA as a drug product for any indication, and in 2023 the agency placed it in Category 2 of its bulk drug substances review for compounding, a category reserved for substances flagged with significant safety risks under the conditions evaluated. The World Anti-Doping Agency lists it among non-approved substances prohibited at all times in sport. Every vial Real Peptides ships is labelled research use only, not for human or veterinary consumption. This article is educational: we do not provide dosing, preparation or administration guidance for any catalogue compound, because these are laboratory materials rather than medicines.

BPC 157 Compared With Other Peptides in Repair Research

Researchers new to this literature often conflate four very different molecules. The table sets out what each one is structurally, what published research actually examines, and how the regulatory picture differs.

Compound	Structure and class	What published research examines	Regulatory footing	Bottom line for a research buyer
BPC 157	Synthetic 15-amino-acid pentadecapeptide, GEPPPGKPADDAGLV, CAS 137525-51-0	Rodent gut mucosal injury, tendon and ligament transection, nerve injury, angiogenic signalling via VEGFR2 and eNOS	Not an approved drug; FDA Category 2 bulk substance for compounding since 2023; prohibited in sport	Deepest preclinical record of the four and the thinnest human record. Verify salt form and mass spectrometry data on every lot.
TB-500	Synthetic peptide related to thymosin beta-4, an actin-binding regulatory protein	Cell migration and actin dynamics in animal wound and cardiac injury models	Not an approved drug; prohibited in sport	Often discussed alongside the pentadecapeptide, though the mechanisms described in the literature are genuinely distinct. Check which fragment a supplier is actually selling.
KPV	Tripeptide Lys-Pro-Val, the C-terminal fragment of alpha-MSH	Anti-inflammatory signalling in rodent colitis and skin inflammation models	Not an approved drug	A far simpler molecule, cheaper to synthesise, with a narrower literature centred on inflammation rather than structural repair.
GHK-Cu	Copper-binding tripeptide Gly-His-Lys complexed with copper(II)	Collagen and extracellular matrix gene expression in dermal cell and animal studies	Used in cosmetic formulations; not an approved drug for systemic indications	Best characterised of the four in skin research. The blue colour in solution is the copper complex, not a defect.

What If: Common Sourcing and Handling Scenarios

What if the certificate of analysis does not match the expected mass?

Reject the lot and ask the supplier for the raw analytical trace. The expected molecular weight for the free base is roughly 1419.5 g/mol, and salt form shifts the observed mass, which is exactly why acetate or arginate should be stated on the certificate rather than assumed. A mass spectrometry result that does not resolve near the expected value means the vial contains something other than the intended pentadecapeptide, and no purity percentage rescues a failed identity check.

What if a supplier describes the compound as a treatment or an approved product?

Treat that as a compliance red flag and source elsewhere. No regulator has approved this pentadecapeptide as a drug product for any indication, and a vendor comfortable misstating regulatory status is equally comfortable misstating analytical results. Legitimate research suppliers describe what the published literature reports in animal models. They do not describe outcomes for a person, and they do not offer preparation or administration guidance.

What if published studies used oral rather than parenteral routes?

Expect both in the literature and do not treat them as equivalent. Research reports comparative stability of the peptide in human gastric juice, which is why rodent work has examined oral delivery, including via drinking water, alongside parenteral routes. Route materially changes exposure, so a finding from an oral rodent model is not interchangeable with an injected one, and neither transfers cleanly to human pharmacology, which remains uncharacterised.

What if two suppliers quote very different prices for the same nominal purity?

Ask what the price difference is buying. Peptide costs track synthesis scale, purification passes and the depth of analytical work behind each batch, and a 99 percent claim with no accompanying HPLC chromatogram or mass spectrometry trace is a marketing number rather than a measurement. Across the supplier documentation our team reviews, the cheapest lots are most often the ones where third-party verification is described but never published.

The Unglamorous Truth About What Is Actually Known

Let's be direct about this: the evidence base for BPC 157 is broad, internally consistent, and almost entirely preclinical. Three decades of rodent studies, much of it from a small cluster of research groups, very little independent human data, and no established human pharmacokinetic profile. That combination is genuinely interesting to a researcher and genuinely insufficient for anything else. The literature does not specify human safety thresholds, effective exposure ranges, or long-term outcomes, and any source that speaks with certainty about those things has moved from science into sales.

For researchers sourcing material, our BPC-157 research overview goes deeper into the published preclinical record, while the catalogue listings for BPC-157 10mg and the BPC-157 capsule format set out small-batch synthesis and third-party testing details. Every batch certificate is published openly, and the same verification standard applies across the wider research peptide catalogue.

BPC 157 occupies an unusual position in peptide science: a molecule with a remarkably consistent animal literature and almost no matching human record. That asymmetry is the whole story. The interesting question was never whether the rodent findings are real, because they have been replicated often enough to take seriously. It is whether mechanisms mapped in animals with different gut chemistry, different healing timelines and far tidier confounders survive translation. Until that work exists, the label on the vial is the most accurate sentence anyone has written about the compound.

References

Peer-reviewed sources on BPC-157 indexed in PubMed, listed for research context. Real Peptides supplies BPC-157 for laboratory research use only.

Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS journal : the musculoskeletal journal of Hospital for Special Surgery, 2025. PMID 40756949. doi:10.1177/15563316251355551
Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel, Switzerland), 2025. PMID 40005999. doi:10.3390/ph18020185
Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current reviews in musculoskeletal medicine, 2025. PMID 40789979. doi:10.1007/s12178-025-09990-7
Stable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats-A Review. Pharmaceuticals (Basel, Switzerland), 2024. PMID 39204186. doi:10.3390/ph17081081
From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management. International journal of molecular sciences, 2026. PMID 41898733. doi:10.3390/ijms27062876
BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase. International journal of molecular sciences, 2026. PMID 42278509. doi:10.3390/ijms27114984
Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury. Scientific reports, 2026. PMID 42204242. doi:10.1038/s41598-026-55449-1
Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint diseases and related surgery, 2026. PMID 42542926. doi:10.52312/jdrs.2026.2951

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add vials.

Start a pack

Questions

BPC 157 is a synthetic pentadecapeptide, a chain of 15 amino acids with the sequence GEPPPGKPADDAGLV and CAS number 137525-51-0. The sequence corresponds to a fragment of a protein identified in human gastric juice. It is a research-use-only compound studied almost exclusively in animal models, and it is not an approved drug.

In published research it is used to study tissue injury in animal models: gastrointestinal mucosal damage including NSAID-induced lesions and experimental colitis, transected tendon and ligament, muscle and peripheral nerve injury, and vascular occlusion. These are laboratory research questions, not approved medical indications, and human clinical evidence remains very limited.

The BPC 157 peptide is a 15-residue synthetic chain built by solid-phase peptide synthesis, supplied as a lyophilised powder, usually as an acetate salt. Its molecular formula is C62H98N16O22 with a molecular weight of roughly 1419.5 g/mol. It is classified as a research chemical, not a medicine, and carries no regulatory approval.

Laboratories use the BPC 157 peptide to investigate repair and inflammation signalling in animal and cell models. Reported research focuses on angiogenic pathways involving VEGFR2, Akt and eNOS, cytokine expression such as TNF-alpha and IL-6, and fibroblast migration through the FAK-paxillin pathway. All published work of this kind is preclinical.

For researchers, it is useful as a probe compound in preclinical injury and inflammation models where angiogenesis and cytokine signalling are the variables of interest. It is not established as good for any human condition, because controlled human trials and human pharmacokinetic data are absent from the published literature.

It is made of 15 amino acids in fixed order: glycine, glutamic acid, three prolines, glycine, lysine, proline, alanine, two aspartic acids, alanine, glycine, leucine and valine. Research-grade material is chemically synthesised rather than extracted from any tissue, and is typically supplied as an acetate salt.

It is produced by solid-phase peptide synthesis, where the 15-residue chain is assembled one amino acid at a time on a resin support using Fmoc protecting-group chemistry. The crude product is then cleaved from the resin, purified by reverse-phase HPLC, and confirmed by mass spectrometry before lyophilisation into powder form.

The literature describes pathways rather than a receptor, because no high-affinity binding site for the peptide has been characterised. Studies report upregulation of VEGFR2 with downstream Akt and eNOS activation, interaction with the nitric oxide system in both directions, and effects on fibroblast migration via FAK-paxillin signalling in cell culture.

It can be purchased legally as a research chemical for laboratory use in many jurisdictions, but it is not approved by the FDA as a drug product and was placed in Category 2 of the agency's bulk drug substances review for compounding in 2023. Buyers should confirm the rules that apply in their own jurisdiction.

They are structurally unrelated. BPC 157 is a 15-amino-acid sequence derived from a gastric juice protein, while TB-500 relates to thymosin beta-4, an actin-binding protein. Research on the former centres on angiogenic and gastrointestinal models; research on the latter centres on actin dynamics and cell migration. Neither is an approved drug.

A usable certificate states the sequence, CAS number 137525-51-0, molecular formula and weight, the salt form, HPLC purity with the supporting chromatogram, and a mass spectrometry result confirming identity. It should also carry a batch or lot number that ties the document to the specific vial. Identity data matters more than a purity headline.

No. Real Peptides supplies research-use-only compounds to laboratories and researchers, so we do not provide dosing, preparation, timing or administration guidance of any kind. What we do publish is analytical documentation: sequence, identity, purity testing and batch certificates, so researchers can verify exactly what a vial contains.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA